Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
04:05pm, Wednesday, 24'th Apr 2024
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinic
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunoth
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
05:10pm, Monday, 22'nd Apr 2024
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
05:06pm, Monday, 22'nd Apr 2024
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
Cidara Therapeutics Announces Reverse Stock Split
08:49am, Monday, 22'nd Apr 2024
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer mouse model
Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC) Abstracts to include precl
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
08:00am, Monday, 12'th Feb 2024
SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
04:30pm, Monday, 29'th Jan 2024
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
12:01pm, Tuesday, 26'th Dec 2023
Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
07:30am, Friday, 22'nd Dec 2023
SAN DIEGO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) today announced REZZAYO (rezafungin acetate) has been approved in the European Union (EU) for the treatment of inv
First in class, multi-specific CD73/PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
08:00am, Wednesday, 06'th Dec 2023
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing therapies designed to save lives and improve the standard of care for patients facing
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
08:00am, Thursday, 30'th Nov 2023
Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time
Cidara Therapeutics: Reduced Risk Due To Janssen's Decision And Progress In The Oncology Pipeline
07:48pm, Friday, 22'nd Sep 2023
Janssen's decision to proceed with CD388 further de-risks Cidara Therapeutics (CDTX) and validates the potential of the Cloudbreak platform. Combined with impressive preclinical data by oncology candi
